Overview

Treatment of Acute Ischemic STroke With Edaravone Dexborneol II

Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This study is a multicentre, randomized, double-blind, placebo parallel controlled, investigator-sponsored study that aims to investigate the efficacy and safety of Edaravone Dexborneol treatment in patients with acute ischemic stroke who had received early reperfusion therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Beijing Tiantan Hospital
Treatments:
Edaravone